COMPANY
Clinical Phase 2
Keywords: protein engineering oncology hematology hematologic malignancies solid tumors B-cell Acute Lymphoblastic Leukemia Large B-cell Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Marginal Zone Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Burkitt Lymphoma Primary Mediastinal Large B-cell Lymphoma Non Hodgkin Lymphoma Mixed Phenotype Acute Leukemia HER2 Expressing Solid Tumors VNX-101 VNX-202
Profile checked Oct 10, 2026
Timeline
- Trial start Phase 1/Phase 2: Gene Therapy for HER-Positive Cancer (SENTRY-HER2) source ↗
- Trial start Phase 1/Phase 2: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) source ↗
Upcoming milestones
- 2027-06 (ESTIMATED) · Phase 1/Phase 2 · Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) · NCT06533579
- 2033-09 (ESTIMATED) · Phase 1/Phase 2 · Gene Therapy for HER-Positive Cancer (SENTRY-HER2) · NCT07192432
Estimated primary completion per ClinicalTrials.gov. Dates move.
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Phase 1/Phase 2 | Recruiting | May 30, 2025 | 2027-06 (estimated) |
| NCT07192432 | Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | Phase 1/Phase 2 | Recruiting | Nov 18, 2025 | 2033-09 (estimated) |
